Billionaire Israel Englander invests money in 2 shares “Strong purchase”
After the wild journey in 2020, where is the market going here? Major steps have been taken in the COVID-19 vaccine race, but the short-term picture remains unclear, blurred by the resurgence of the virus and a dead end on Capitol Hill. In times like these, investment greats can serve as a source of inspiration, namely the billionaire Israel “Izzy”
; Englander. Who exactly is Englander? The legend, who started trading stocks when he was in high school, began his career as an intern at the investment firm Oppenheimer, and later bought a place on the American Stock Exchange, where he would serve as a floor broker, trader and specialist. In 1989, together with Ronald Sheare, Englander founded the hedge fund Millennium Management. As proof of his stellar experience, the guru took the $ 35 million that set up the fund and turned it into more than $ 40 billion in assets under management. With his personal net worth of $ 7.2 billion, it’s no wonder Wall Street pays attention when Englander makes a move. With that in mind, our focus shifted to Millennium’s latest 13F bid, which reveals the stock the fund raised in the third quarter. Concluding two tickers in particular, the TipRanks database revealed that both names reach a consensus among analysts on Strong Buying. Moreover, the analyst community sees the huge potential for growth for each of them. G1 Therapeutics (GTHX) Introducing to the table a deep understanding of the biology of cancer and extensive experience in drug discovery, G1 Therapeutics is working to develop therapies that could potentially improve the lives of patients battling the deadly disease. Before a key regulatory decision, the street hit the table with that name. In the third quarter, Englander and Millennium took a new stake in GTHX. With the trigger for 555,937 shares, the holding’s value reached $ 6,421,000. Addressing the analyst community, Needham’s Chad Messer told customers he had high hopes before the February 15 PDUFA date for trilacyclib, his therapy was designed to improve outcomes for cancer patients treated with chemotherapy. The NDA of therapy was adopted in August as a priority review based on the results of three randomized clinical trials in small cell lung cancer (SCLC), with the FDA indicating that it does not plan to hold a meeting of the Advisory Committee (AdComm). the first CDK4 / 6 inhibitor used to treat chemoinduced bone marrow toxicity, Messer argues that the lack of AdComm is “significant.” In stating this, he stated: “We believe this reflects the agency’s assessment of unmet needs, comfort with the safety profile of the CDK4 / 6 class and the efficacy profile of trilacyclib.” GTHX will also focus on the inclusion of trilacyclib in NCCN guidelines. . It should also be noted that the main Phase 3 study evaluating the candidate for metastatic colorectal cancer (mCRC) will begin by the end of the year. In addition to the good news, GTHX and its partner, Boehringer Ingelheim, are preparing to launch trilacyclib, with companies covering approximately 2,500 oncologists and providing educational materials on trilacyclib use before treatment and the benefits of preserving many genera. If this was not sufficient, the rintodestrant (its selective estrogen receptor degrader (SERD) in development for the treatment of estrogen receptor-positive (ER +) breast cancer) plus a combination of palbocyclib study was able to complete recording earlier than expected, reflecting “the attractiveness of a comprehensive oral treatment regimen during a global pandemic,” according to Messer. Taking data scheduled for the second quarter of 2021, the analyst believes that “positive reporting can be an important driver of value.” In line with his optimistic approach, Messer confirmed the purchase price and the price of $ 74, which shows 417% potential for increase. (To view Messer’s recording, click here) Do other analysts agree? They are. In the last three months, only purchase ratings have been issued, namely 3. Therefore, the message is clear: GTHX is a strong purchase. Given the $ 59 average price target, shares could rise 312% next year. (See GTHX Stock Analysis for TipRanks) Epizyme (EPZM) Also in the fight against good cancer control as well as other serious diseases, Epizyme wants to find new treatments with new epigenetic drugs. Although the company is facing a headwind over the product’s recent launch, several Street members believe big things are in sight. Millennium bought 461,258 shares in the third quarter, reflecting a new position for the hedge fund. As for the value of the farm, it reaches $ 5,503,000. Writing for Wedbush, 5-star analyst David Nirengarten points out that the pandemic has limited visits to oncologists and therefore sales of Tazverik (the company’s follicular lymphoma treatment) are more low than expected. He points out that “the pandemic shifts the start-up curve to a ‘frequency model’ rather than a distribution model, as there are a limited number of patients to draw from if they delay office visits” with patients waiting seek treatment until they experience symptoms of progression. In addition, although the launch is virtual and doctors’ awareness is high, doctors are reluctant to prescribe a new drug without examining the patient in person. With this in mind, Nierengarten remains optimistic about the therapy. “Despite these opposing winds, Tazverik came close to our estimates and won market share, including initial second-line sales. We expect more significant second-line sales to begin in 2021 and gradually include them in our launch curve, “the analyst explained. When it comes to therapy, Nierengarten says it’s too early to draw any conclusions. emphasizes, however, the fact that the duration of the response was relatively long and patients were treated earlier in the registration process. ”In addition, headwind versus switching therapies becomes a tailwind for Tazverik maintenance once the patient is on This is likely to contribute more meaningfully to 2H21 revenue and potential revenue superiority, “he added. Summing it all up, Nierengarten commented: “At current levels, we believe that investors are too negative about Tazverik’s potential and patience must be rewarded.” Based on all of the above, Nierengarten joins the bulls, reaffirming the rating for superiority and a target price of $ 27. This goal expresses his confidence in EPZM’s ability to climb 122% higher next year. (To watch the Nierengarten record, click here) Most other analysts echo Nierengarten’s mood. 3 purchases and 1 hold add to the consensus rating of a strong purchase. With an average price of $ 23.25, the potential for increase reaches 91%. (See EPZM’s stock analysis for TipRanks.) To find good ideas for health stocks trading at attractive ratings, visit TipRanks’ Best Buy Stocks, a newly created tool that brings together all insights into TipRanks ownership. Disclaimer: The views expressed in this article are those of the analysts submitted. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.